Valuation
PharmaceuticalsLive · Yahoo FinancePrice
$205.03
52-Week Range
Decision Context
Scores are balanced across the six engines. No single dimension dominates — this is consistent with a stable, mid-tier quality business.
Based on filing period ending Jun 2026
FisclearScore is a quantitative model using public financial data and sector median benchmarks (refreshed monthly). Not financial advice. Always conduct independent due diligence.
Macro Context
Fed Funds Rate
3.63%
Accommodative
10-Year Treasury
4.47%
2026-06-01
Unemployment
4.2%
Near full employment
CPI Index
332.6
2026-06-01
M2 Money Supply
$23.2T
2026-06-01
The Federal Funds rate stands at 3.63% — a moderately elevated rate environment that raises borrowing costs across the economy; 10-year Treasury yields are at 4.47%, setting the benchmark for long-term corporate borrowing; Unemployment stands at 4.2%; Industrial production index is at 102.6; M2 money supply is $23.2T; CPI index stands at 332.6.
SWOT Analysis — BIIB
Inflationary BoomStrengths
Total Assets: $29.4B (+5.0% YoY) — Total assets grew 5% — the company's resource base expanded.
Weaknesses
Operating Cash Flow: $2.2B (-23.3% YoY) — Operating cash flow fell 23% but remained positive.
EPS (Diluted): $8.79 (-21.4% YoY) — Earnings per share fell 21%.
Net Income: $1.3B (-20.8% YoY) — Profit fell 21% but remained positive.
Gross Profit: $11.6B (-6.3% YoY) — Gross profit declined 6% — costs are growing faster than revenue.
Opportunities
No clear opportunities identified at this time.
Threats
Gross margin compressed by 10.7pp — input costs or pricing pressure is eroding profitability on each dollar of revenue.
Financial Charts
Year-over-Year Changes
Operating Cash Flow
$2.2B
was $2.9B
Operating cash flow fell 23% but remained positive.
EPS (Diluted)
$8.79
was $11.18
Earnings per share fell 21%.
Net Income
$1.3B
was $1.6B
Profit fell 21% but remained positive.
Gross Profit
$11.6B
was $12.4B
Gross profit declined 6% — costs are growing faster than revenue.
Total Assets
$29.4B
was $28.0B
Total assets grew 5% — the company's resource base expanded.
Risk Flags
0 high · 1 medium · 0 low- ◈ Medium
Gross margin compressed by 10.7pp — input costs or pricing pressure is eroding profitability on each dollar of revenue.
Price History
Technical Signals
Daily closes · 1-year dataLatest News
via FinnhubFiling History — BIIB
Get the weekly digest
5 company reports + macro context every week, free. No spam.
- Unlimited goal simulations
- 5 free company report summaries per day
- Weekly financial insights newsletter
External Links
Trade BIIB
Links open broker research pages. Not an endorsement or recommendation.
Research BIOGEN INC.
Data sourced from SEC EDGAR, FRED (Federal Reserve Economic Data), and Yahoo Finance. For informational purposes only. Not financial advice.